Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 489,900 shares, an increase of 123.2% from the January 15th total of 219,500 shares. Approximately 6.4% of the shares of the company are sold short. Based on an average daily trading volume, of 340,700 shares, the days-to-cover ratio is presently 1.4 days.
Immix Biopharma Trading Down 5.6 %
NASDAQ IMMX opened at $3.06 on Tuesday. The company has a 50 day moving average of $5.30 and a 200-day moving average of $3.92. Immix Biopharma has a 1-year low of $1.40 and a 1-year high of $7.75.
Insider Transactions at Immix Biopharma
In other news, Director Jason Hsu bought 31,000 shares of the company’s stock in a transaction dated Monday, December 11th. The stock was bought at an average price of $4.67 per share, with a total value of $144,770.00. Following the completion of the acquisition, the director now owns 813,000 shares of the company’s stock, valued at $3,796,710. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 55.90% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Immix Biopharma
Immix Biopharma Company Profile
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
- Five stocks we like better than Immix Biopharma
- How to Invest in Biotech Stocks
- Lowe’s levels up: A blueprint for tomorrow’s home improvement
- Dividend Capture Strategy: What You Need to Know
- Is Duke Energy stock ready to power up in 2024?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Hershey stock presents investors a sweet buy-the-dip opportunity
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.